-$0.75 Earnings Per Share Expected for Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) This Quarter

Wall Street analysts forecast that Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) will announce earnings per share of ($0.75) for the current quarter, Zacks reports. Zero analysts have made estimates for Eyegate Pharmaceuticals’ earnings. Eyegate Pharmaceuticals reported earnings of ($1.05) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 28.6%. The firm is scheduled to issue its next earnings results on Tuesday, November 12th.

On average, analysts expect that Eyegate Pharmaceuticals will report full-year earnings of ($1.95) per share for the current financial year. For the next fiscal year, analysts forecast that the firm will report earnings of ($3.45) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Eyegate Pharmaceuticals.

Eyegate Pharmaceuticals (NASDAQ:EYEG) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.15.

Separately, ValuEngine raised shares of Eyegate Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd.

In other news, major shareholder Armistice Capital Master Fund purchased 605,001 shares of the stock in a transaction dated Monday, September 30th. The shares were purchased at an average cost of $3.12 per share, with a total value of $1,887,603.12. Corporate insiders own 47.50% of the company’s stock.

A hedge fund recently bought a new stake in Eyegate Pharmaceuticals stock. Susquehanna International Group LLP acquired a new position in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 222,297 shares of the specialty pharmaceutical company’s stock, valued at approximately $53,000. Susquehanna International Group LLP owned approximately 0.49% of Eyegate Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

EYEG stock traded up $0.29 during mid-day trading on Tuesday, hitting $4.05. The stock had a trading volume of 14,400 shares, compared to its average volume of 23,695. The firm has a market capitalization of $15.09 million, a P/E ratio of -0.90 and a beta of 2.16. Eyegate Pharmaceuticals has a 52 week low of $2.25 and a 52 week high of $9.60. The firm has a fifty day simple moving average of $3.42 and a 200 day simple moving average of $1.32.

About Eyegate Pharmaceuticals

EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.

See Also: Risk Tolerance and Your Investment Decisions

Get a free copy of the Zacks research report on Eyegate Pharmaceuticals (EYEG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.